FDA Approves Ontruzant (trastuzumab-dttb), a Biosimilar to Herceptin

Article Link: FDA Approves Ontruzant (trastuzumab-dttb), a Biosimilar to Herceptin

January 18, 2019 — FDA today approved Ontruzant (trastuzumab-dttb), a biosimilar to U.S.-licensed Herceptin (trastuzumab).
A biosimilar product is a biological product that is approved based on a showing that it is highly similar to an already-FDA…

Source: FDA New Drug Approvals